Enhanced Proton Treatment with a LDLR-ligand Peptide-conjugated Gold Nanoparticles Targeting the Tumor Microenvironment in an Infiltrative Brain Tumor Model
Overview
Affiliations
The tumor microenvironment (TME) of glioblastoma malforms (GBMs) contains tumor invasiveness factors, microvascular proliferation, migratory cancer stem cells and infiltrative tumor cells, which leads to tumor recurrence in the absence of effective drug delivery in a Blood Brain Barrier (BBB)-intact TME and radiological invisibility. Low-density lipoprotein receptor (LDLR) is abundant in the blood brain barrier and overexpressed in malignant glioma cells. This study aimed to treat the TME with transmitted proton sensitization of LDLR ligand-functionalized gold nanoparticles (ApoB@AuNPs) in an infiltrative F98 glioma rat model. BBB-crossing ApoB@AuNPs were selectively taken up in microvascular endothelial cells proliferation and pericyte invasion, which are therapeutic targets in the glioma TME. Proton sensitization treated the TME and bulk tumor volume with enhanced therapeutic efficacy by 67-75% compared to that with protons alone. Immunohistochemistry demonstrated efficient treatment of endothelial cell proliferation and migratory tumor cells of invasive microvessels in the TME with saving normal tissues. Taken together, these data indicate that the use of LDLR ligand-functionalized gold nanoparticles is a promising strategy to treat infiltrative malignant glioma while overcoming BBB crossing.
Carbone G, Mariano S, Gabriele A, Cennamo S, Primiceri V, Aziz M Pharmaceutics. 2025; 17(2).
PMID: 40006543 PMC: 11859620. DOI: 10.3390/pharmaceutics17020176.
New Trends in Brain Shuttle Peptides.
Prades R, Teixido M, Oller-Salvia B Mol Pharm. 2025; 22(3):1100-1109.
PMID: 39899901 PMC: 11881811. DOI: 10.1021/acs.molpharmaceut.4c01327.
Pericytes in Glioblastoma: Hidden Regulators of Tumor Vasculature and Therapy Resistance.
Salazar-Saura I, Pinilla-Sala M, Megias J, Navarro L, Rosello-Sastre E, San-Miguel T Cancers (Basel). 2025; 17(1.
PMID: 39796646 PMC: 11718950. DOI: 10.3390/cancers17010015.
The multifaceted therapeutical role of low-density lipoprotein receptor family in high-grade glioma.
Mastrantuono E, Ghibaudi M, Matias D, Battaglia G Mol Oncol. 2024; 18(12):2966-2976.
PMID: 39276062 PMC: 11619799. DOI: 10.1002/1878-0261.13730.
Korolkov I, Zaboronok A, Izbasar K, Bekbol Z, Lissovskaya L, Zibert A Pharmaceutics. 2024; 16(6).
PMID: 38931918 PMC: 11207315. DOI: 10.3390/pharmaceutics16060797.